Related Experiment Video

Updated: May 1, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

5.7K

Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors

Piro Lito1, Anna Saborowski2, Jingyin Yue3

  • 1Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA; Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

Cancer Cell
|April 22, 2014
PubMed

Insights

MEK inhibitors are less effective in KRAS mutant cancers because CRAF activates MEK differently than BRAF. Disrupting RAF-MEK complexes improves MEK inhibitor efficacy in these tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Signaling

Background:

  • Mitogen-activated protein kinase (MEK) inhibitors show clinical activity in BRAF(V600E) mutant melanomas.
  • Their efficacy is limited in KRAS-mutant tumors, suggesting distinct signaling mechanisms.

Purpose of the Study:

  • To investigate the differential response of BRAF(V600E) and KRAS-mutant tumors to MEK inhibitors.
  • To elucidate the mechanisms underlying MEK inhibitor resistance in KRAS-mutant cancers.

Main Methods:

  • RNA interference (RNAi) screen in a KRAS-mutant cancer model.
  • Analysis of MEK inhibitor potency and ERK signaling suppression.
  • Investigation of RAF-MEK complex formation and disruption.

Main Results:

  • MEK inhibitors suppressed ERK signaling more potently in BRAF(V600E) than in KRAS-mutant tumors.
  • CRAF knockdown enhanced MEK inhibition in KRAS-mutant models.
  • MEK activated by CRAF was less susceptible to MEK inhibitors compared to BRAF(V600E)-activated MEK.
  • MEK inhibitors induced RAF-MEK complexes in KRAS-mutant models, and disrupting these complexes enhanced CRAF-dependent ERK signaling inhibition.

Conclusions:

  • Differential activation of MEK by BRAF and CRAF contributes to varying MEK inhibitor sensitivity.
  • Targeting RAF-MEK complex formation or utilizing newer MEK inhibitors that impair CRAF-mediated reactivation may overcome resistance in KRAS-mutant cancers.

More Related Videos

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells06:44

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells

Published on: March 1, 2024

1.9K
Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

2.4K

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
5.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K